# Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

> **NCT02062502** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 611 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** VARIVAX™ New Seed Process
- **BIOLOGICAL:** VARIVAX™ 2007 process
- **BIOLOGICAL:** M-M-R II™

## Key facts

- **NCT ID:** NCT02062502
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-07
- **Primary completion:** 2015-02-24
- **Final completion:** 2015-10-13
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02062502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02062502, "Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02062502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*